- PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent StudyYan, Gao; Zhang, Liling; Li, Wenyu; Wei, Xu; Feng, Ru; Li, Xue-Ping; Chen, Yu; Wu, Huijing; Wang, Xiaoxiao; Bai, Bing; Huang, Huiqiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit StudyCai, Qingqing; Liu, Panpan; Xia, Yi; Cai, Jun; Huang, Huiqiang; Li, Zhiming; Zhou, Hui; Li, Yajun; Wang, Hanyu; Huang, Ying; Yan, Gao; Pan, Xueyi64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 3
- Phase 2 study of tislelizumab monotherapy in previously treated, locally advanced, unresectable or metastatic microsatellite instability-high/mismatch repair-deficient solid tumors: Gynecological cancer subgroupWang, Dong; Zhang, Naiyi; Zang, Aimin; Wang, Jing; Huang, Yi; Shen, Lin; Li, Jian; Zhang, Yanqiao; Liu, Tianshu; Deng, Yanhong; Xu, Yaling; Li, Zhezhen; Wang, Yidi; Gao, Yunong
会议论文
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
3被引15阅读
